Serologic Assay Validation and Proficiency Testing of HIL-214 in Adults

• Sponsor: HilleVax (Industry)
• Overall Status: Recruiting
• CT.gov ID: NCT05972733
• Collaborator: (none)
• Enrollment: 80
• Locations: 2
• Arm: 1
• Anticipated Duration (Months): 4.5
• Patients Per Site: 40
• Patients Per Site Per Month: 8.8

Study Details

Study Description

Brief Summary

The purpose of this trial is to obtain serum for proficiency testing to confirm assay validity is maintained following the dosing of adults with a pediatric dose of HIL-214.

Condition or Disease	Intervention/Treatment	Phase
Gastroenteritis	Biological: HIL-214	Phase 2

Detailed Description

This single-arm trial serves to obtain serum for proficiency testing to confirm assay validity is maintained. Exploratory aspects of this trial include evaluating additional assays used for the assessment of immune responses to HIL-214 in peripheral-blood samples. Given the large volume of blood required, the pediatric dose will be tested in healthy adults. The main scientific rationale for the trial is to identify immune assays that can assess the generation of serum antibodies or cell-mediated immunity (CMI) specific to norovirus strains not represented in the HIL-214 vaccine (i.e. cross-reactivity).

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 80 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Intervention Model Description: Single-arm, Open-label TrialSingle-arm, Open-label Trial
• Masking: None (Open Label)
• Primary Purpose: Prevention
• Official Title: Phase 2, Single-arm, Open-label Trial for Serologic Assay Validation, Proficiency Testing, Safety and Immunogenicity of the Intramuscular HIL-214 Norovirus Vaccine in Adults Aged 18 to 49 Years
• Actual Study Start Date: Aug 2, 2023
• Anticipated Primary Completion Date: Sep 7, 2023
• Anticipated Study Completion Date: Dec 18, 2023

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Open Arm Study One dose given to all participants	Biological: HIL-214; HIL-214

Outcome Measures

Primary Outcome Measures

1. Primary Immunogenicity for Panel Formation [6 months]

   For the 80 subjects enrolled in the trial, the serum samples that will be collected will be used to produce a proficient assay panel based on immunogenicity results of the initial testing. This panel that is formed will be used for further analysis in other clinical trials.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 49 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• Male or female subjects aged 18 to 49 years, inclusive.

• Individuals who are in good health at the time of entry into the trial as determined by medical history, physical examination (including vital signs) and clinical judgment of the investigator.

• The individual signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any trial procedures, after the nature of the trial has been explained according to regulatory requirements.

• Individuals willing and able to comply with trial procedures and are available for the duration of follow-up.

Exclusion Criteria:

• Females who are pregnant or breastfeeding.

• Gastroenteritis within 14 days before planned dosing (can warrant delay of trial vaccine administration).

• Known hypersensitivity or allergy to any of the HIL-214 components (including excipients).

• Known or suspected impairment/alteration of immune function, including history of any autoimmune disease or neuro-inflammatory disease.

• Any serious chronic or progressive disease (including hepatitis B or C).

• Previous exposure to an experimental norovirus vaccine.

• Subject or subject's first-degree relatives are involved in the trial conduct.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Pennisula Research Associates	Rolling Hills Estates	California	United States	90274
2	Clinical Research Atlanta	Stockbridge	Georgia	United States	30281

Sponsors and Collaborators

• HilleVax

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: HilleVax
• ClinicalTrials.gov Identifier: NCT05972733
• Other Study ID Numbers: NOR-215
• First Posted: Aug 2, 2023
• Last Update Posted: Aug 4, 2023
• Last Verified: Aug 1, 2023

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Gastroenteritis

Study Results

No Results Posted as of Aug 4, 2023